WO2004007723A3 - Genes - Google Patents

Genes Download PDF

Info

Publication number
WO2004007723A3
WO2004007723A3 PCT/GB2003/003093 GB0303093W WO2004007723A3 WO 2004007723 A3 WO2004007723 A3 WO 2004007723A3 GB 0303093 W GB0303093 W GB 0303093W WO 2004007723 A3 WO2004007723 A3 WO 2004007723A3
Authority
WO
WIPO (PCT)
Prior art keywords
fragilis
stella
primordial germ
cells
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2003/003093
Other languages
French (fr)
Other versions
WO2004007723A2 (en
Inventor
Mitinori Saitou
Azim Surani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge University Technical Services Ltd CUTS
Original Assignee
Cambridge University Technical Services Ltd CUTS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60330565T priority Critical patent/DE60330565D1/en
Priority to CA002493675A priority patent/CA2493675A1/en
Priority to AT03764023T priority patent/ATE452189T1/en
Priority to EP03764023A priority patent/EP1521832B1/en
Priority to JP2004520898A priority patent/JP2005532808A/en
Priority to AU2003255720A priority patent/AU2003255720B2/en
Application filed by Cambridge University Technical Services Ltd CUTS filed Critical Cambridge University Technical Services Ltd CUTS
Publication of WO2004007723A2 publication Critical patent/WO2004007723A2/en
Publication of WO2004007723A3 publication Critical patent/WO2004007723A3/en
Anticipated expiration legal-status Critical
Priority to US11/038,676 priority patent/US7488803B2/en
Priority to US12/356,351 priority patent/US20090210954A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

We described primordial germ cell expressed genes, Fragilis and Stella. The sequences and uses of human Stella and Fragilis are disclosed, as well as several related mouse sequences related to Fragilis. Stella and Fragilis which are markers for primordial germ cells and may be used to identify such cells in cell populations. They may also be used for diagnosing, treating and/or preventing diseases such as cancers.
PCT/GB2003/003093 2002-07-17 2003-07-17 Genes Ceased WO2004007723A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002493675A CA2493675A1 (en) 2002-07-17 2003-07-17 Genes
AT03764023T ATE452189T1 (en) 2002-07-17 2003-07-17 ANTI-FRAGILIS ANTIBODIES AND THEIR USES
EP03764023A EP1521832B1 (en) 2002-07-17 2003-07-17 Anti-fragilis antibody and uses thereof
JP2004520898A JP2005532808A (en) 2002-07-17 2003-07-17 gene
AU2003255720A AU2003255720B2 (en) 2002-07-17 2003-07-17 Genes
DE60330565T DE60330565D1 (en) 2002-07-17 2003-07-17 Anti-fragilis antibodies and their uses
US11/038,676 US7488803B2 (en) 2002-07-17 2005-01-18 Antibodies to the extracellular domain of human Fragilis polypeptide and methods of making said antibodies
US12/356,351 US20090210954A1 (en) 2002-07-17 2009-01-20 Genes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0216727.8A GB0216727D0 (en) 2002-07-17 2002-07-17 Genes
GB0216727.8 2002-07-17
US39731002P 2002-07-19 2002-07-19
US60/397,310 2002-07-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/038,676 Continuation-In-Part US7488803B2 (en) 2002-07-17 2005-01-18 Antibodies to the extracellular domain of human Fragilis polypeptide and methods of making said antibodies

Publications (2)

Publication Number Publication Date
WO2004007723A2 WO2004007723A2 (en) 2004-01-22
WO2004007723A3 true WO2004007723A3 (en) 2004-04-01

Family

ID=9940726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/003093 Ceased WO2004007723A2 (en) 2002-07-17 2003-07-17 Genes

Country Status (9)

Country Link
US (2) US7488803B2 (en)
EP (1) EP1521832B1 (en)
JP (1) JP2005532808A (en)
AT (1) ATE452189T1 (en)
AU (1) AU2003255720B2 (en)
CA (1) CA2493675A1 (en)
DE (1) DE60330565D1 (en)
GB (1) GB0216727D0 (en)
WO (1) WO2004007723A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150102075A (en) * 2012-12-28 2015-09-04 베크만 컬터, 인코포레이티드 Compositions for permeabilising fixed blood cells and uses thereof
WO2025064873A2 (en) * 2023-09-20 2025-03-27 The Johns Hopkins University Compositions and methods for treating cancer

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054353A2 (en) * 1998-04-17 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid sequences of normal uterus tissue
WO2001075177A2 (en) * 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tumor markers in ovarian cancer
WO2001077389A2 (en) * 2000-04-05 2001-10-18 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
WO2002012328A2 (en) * 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002029103A2 (en) * 2000-10-02 2002-04-11 Gene Logic, Inc. Gene expression profiles in liver cancer
WO2002057307A2 (en) * 2001-01-18 2002-07-25 Cambridge University Technical Services Limited Genes
WO2002103028A2 (en) * 2001-05-30 2002-12-27 Biomedical Center In silico screening for phenotype-associated expressed sequences

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092037A1 (en) * 2001-07-18 2003-05-15 Osamu Matsuzaki Elk1 phosphorylation related gene

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054353A2 (en) * 1998-04-17 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid sequences of normal uterus tissue
WO2001075177A2 (en) * 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tumor markers in ovarian cancer
WO2001077389A2 (en) * 2000-04-05 2001-10-18 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
WO2002012328A2 (en) * 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002029103A2 (en) * 2000-10-02 2002-04-11 Gene Logic, Inc. Gene expression profiles in liver cancer
WO2002057307A2 (en) * 2001-01-18 2002-07-25 Cambridge University Technical Services Limited Genes
WO2002103028A2 (en) * 2001-05-30 2002-12-27 Biomedical Center In silico screening for phenotype-associated expressed sequences

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 1 June 2001 (2001-06-01), KAWAI ET AL.: "Functional annotation of a full length mouse cDNA collection", XP002261765, retrieved from EMBL Database accession no. Q9D3R8 *
DATABASE EMBL [online] 1 June 2001 (2001-06-01), KAWAI ET AL.: "Functional annotation of a full length mouse cDNA collection", XP002261766, retrieved from EMBL Database accession no. Q9D103 *
DATABASE EMBL [online] 1 June 2001 (2001-06-01), SAITOU ET AL.: "Specification of germ cell fate in mice.", XP002261764, retrieved from EMBL Database accession no. Q99J93 *
DATABASE EMBL [online] 1 November 1998 (1998-11-01), BAIRD ET AL.: "Differenciating embryonal stem cells are a rich source of haematopoietic gene products and suggest erythroid preconditionaing of primitive haematopoietic stem cells", XP002261767, retrieved from EMBL Database accession no. O88728 *
DATABASE EMBL [online] 2 August 1991 (1991-08-02), XP002267449, retrieved from EMBL Database accession no. X57351 *
DATABASE EMBL [online] 26 January 2000 (2000-01-26), XP002261768, retrieved from EMBL Database accession no. AL137226 *
DATABASE EMBL [online] 27 April 1998 (1998-04-27), XP002261769, retrieved from EMBL Database accession no. AA927342 *
DATABASE EMBL [online] 4 May 2002 (2002-05-04), XP002267448, retrieved from EMBL Database accession no. BQ233055 *
DEBLANDRE GISELE A ET AL: "Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 40, 1995, pages 23860 - 23866, XP002267527, ISSN: 0021-9258 *
LEWIN A R ET AL: "MOLECULAR ANALYSIS OF A HUMAN INTERFERON-INDUCIBLE GENE FAMILY", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 199, no. 2, 1991, pages 417 - 423, XP000906854, ISSN: 0014-2956 *
REID L E ET AL: "A SINGLE DNA RESPONSE ELEMENT CAN CONFER INDUCIBILITY BY BOTH ALPHA AND GAMMA INTERFERONS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 86, no. 3, 1989, 1989, pages 840 - 844, XP009024467, ISSN: 0027-8424 *
SAITOU M ET AL: "A molecular programme for the specification of germ cell fate in mice", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 418, no. 6895, 18 July 2002 (2002-07-18), pages 293 - 300, XP002222771, ISSN: 0028-0836 *
SATO M ET AL: "IDENTIFICATION OF PGC7, A NEW GENE EXPRESSED SPECIFICALLY IN PREIMPLANTATION EMBRYOS AND GERM CELLS", MECHANISMS OF DEVELOPMENT, ELSEVIER SCIENCE IRELAND LTD, IE, vol. 113, 2002, pages 91 - 94, XP001120658, ISSN: 0925-4773 *

Also Published As

Publication number Publication date
DE60330565D1 (en) 2010-01-28
AU2003255720B2 (en) 2009-07-30
US20060035326A1 (en) 2006-02-16
WO2004007723A2 (en) 2004-01-22
EP1521832A2 (en) 2005-04-13
JP2005532808A (en) 2005-11-04
GB0216727D0 (en) 2002-08-28
ATE452189T1 (en) 2010-01-15
US7488803B2 (en) 2009-02-10
US20090210954A1 (en) 2009-08-20
AU2003255720A1 (en) 2004-02-02
CA2493675A1 (en) 2004-01-22
EP1521832B1 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
WO2005005601A8 (en) Compositions and methods for treating and diagnosing cancer
WO2006092668A3 (en) Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
WO2009043159A8 (en) Neural tumor stem cells and methods of use thereof
WO2003089619A3 (en) Placental derived stem cells and uses thereof
WO2008057457A3 (en) Antagonists of pcsk9
WO2008057458A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
WO2008060813A3 (en) High affinity antibody antagonists of interleukin-13 receptor alpha 1
WO2004063362A3 (en) Cell cycle progression proteins
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003003906A3 (en) Diagnostic and screening methods for bladder cancer
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
WO2008153662A3 (en) Skin firming and lifting compositions and methods of use
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2004076639A3 (en) Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
WO2006017134A3 (en) Preprimitive streak and mesendoderm cells
WO2003010336A3 (en) Molecular markers for hepatocellular carcinoma
WO2006025028A3 (en) Novel classification method of blood cells and tailor-made therapy and prevention based thereupon
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2008049098A3 (en) ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1
AU2002219137A1 (en) Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer
WO2004044127A3 (en) Stem cell populations
IL149416A0 (en) Human enzymes of the metalloprotease family

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2493675

Country of ref document: CA

Ref document number: 2004520898

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11038676

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003255720

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003764023

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003764023

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11038676

Country of ref document: US